Skip to main content

Table 1 Characteristics of included HIV+ subjects and controls

From: Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life

  pHIVy patients (# = 21) npHIVy patients (# = 19)a HC (# = 40)
Age (years); median (IQR) 27 (24–29) 27 (24–29) 28 (24–31)
Males; patients (%) 7 (33) 12 (63) 19 (47.5)
CD4/μl; median (IQR) 803 (526–1052) 818 (688–1024) 851 (643–1099)
CD4, %; median (IQR) 33.8 (28.7–38.8) 38.1 (31.9–42) 42.9 (39.7–49.4)
CD8/μl; median (IQR) 850 (713–1131) 728 (631–812) 415 (344–571)
CD8, %; median (IQR) 42.8 (32.7–51) 32.3 (28–40.3) 22.2 (22.0–22.6)
CD4/CD8 ratio; median (IQR) 0.8 (0.6–1.2) 1.2 (0.8–1.4) 2.0 (2.0–2.5)
Years with HIV; median (IQR) 27* (0) 4* (3–5.5) NA
HIV viral load < 37 copies/ml; patients 20 19 NA
Hepatitis B surface antigen positive; patients (%) 1 (4.76) 1 (5.26) NA
Hepatitis C virus-antibody positive; patients (%)b 5 (23.81) 1 (5.26) NA
Cytomegalovirus IgG positive; patients (%) 13 (61.90) 7 (36.84) NA
Toxoplasma gondii IgG positive; patients (%) 4 (19.04) 2 (10.52) NA
Treatment prescribed at enrolment:
 PI + 2 NRTI; patients (%) 4 (19) 5 (26) NA
 NNRTI + 2 NRT; patients (%) 3 (14) 8 (42) NA
 INI + 2 NRTI; patients (%) 6 (29) 6 (32) NA
 INI + PI; patients (%) 7 (33) 0 NA
 INI + NNRTI; patients (%) 1 (5) 0 NA
  1. HC healthy controls, IQR interquartile range, NA not applicable, PI protease inhibitor, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non nucleoside reverse transcriptase inhibitor, INI integrase inhibitor, # number
  2. *P < 0.001 (P-value calculation was done by Fisher exact test for categorial variables and unpaired t test for continuous variables)
  3. a 9 patients were heterosexual, 8 homosexual and 2 bisexual. bAll 6 patients were Sustained Virological Responsers (SVR) to previous anti-HCV therapy with Directly Acting Antivirals (DAA)